Evidence map›Paper›PMID 40454268›Full record

ArticleJournal of the Society for Cardiovascular Angiography & Interventions2025

Forward Flow in Patients With Heart Failure and Functional Mitral Regurgitation: The COAPT Trial.

Zachary M Gertz, Philippe Pibarot, Zhipeng Zhou, Michael J Schonning, Björn Redfors, Yanru Li, Saibal Kar, D Scott Lim, Neil J Weissman, David J Cohen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Society for Cardiovascular Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zachary M GertzDivision of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia.
Philippe PibarotDepartment of Medicine, Québec Heart and Lung Institute, Laval University, Québec City, Québec, Canada.
Zhipeng ZhouClinical Trials Center, Cardiovascular Research Foundation, New York, New York.
Michael J SchonningClinical Trials Center, Cardiovascular Research Foundation, New York, New York.
Björn RedforsClinical Trials Center, Cardiovascular Research Foundation, New York, New York.
Yanru LiClinical Trials Center, Cardiovascular Research Foundation, New York, New York.
Saibal KarCardiovascular Institute, Los Robles Regional Medical Center, Thousand Oaks, California.
D Scott LimDivision of Cardiology, University of Virginia, Charlottesville, Virginia.
Neil J WeissmanCardiovascular Core Laboratories, MedStar Health Research Institute, Washington, DC.
David J CohenClinical Trials Center, Cardiovascular Research Foundation, New York, New York.
JoAnn LindenfeldAdvanced Heart Failure, Vanderbilt Heart and Vascular Institute, Nashville, Tennessee.
William T AbrahamDepartment of Medicine, The Ohio State University, Columbus, Ohio.
Michael J MackBaylor Scott & White Heart and Vascular Hospital, Plano, Texas.
Federico M AschCardiovascular Core Laboratories, MedStar Health Research Institute, Washington, DC.
Gregg W StoneThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Heart failure (HF) is characterized by a reduction in forward cardiac output (forward flow), potentially worsened by functional mitral regurgitation (FMR). The impact of reduced forward flow in HF patients with FMR is uncertain, and the outcomes of mitral transcatheter edge-to-edge repair (TEER) according to forward flow levels have not been described. Methods: This study assessed the change in baseline flow in patients with HF and FMR enrolled in the COAPT trial randomized to TEER plus guideline-directed medical therapy (GDMT) compared with GDMT alone. Patients were stratified into tertiles of baseline forward flow using the Doppler-derived stroke volume index. The primary outcome was the composite rate of death or HF hospitalization at 24 months. Clinical, echocardiographic, and outcome measures were assessed. Results: Among patients randomized to GDMT alone, the lowest baseline forward flow tertile was associated with worse outcomes ( Conclusions: In the COAPT trial, lower baseline forward flow was associated with worse outcomes in medically managed patients, and those with low baseline forward flow derived the greatest absolute benefit from TEER. However, measured forward flow did not improve with TEER during the 2-year follow-up.

Indexed as

COAPTechocardiographyfunctional mitral regurgitationheart failuretranscatheter edge-to-edge repair

Identifiers

PMID40454268
PMCPMC12126076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.